Amgen Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Robert A. Bradway
- Full Time Employees
- 31,500
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- One Amgen Center Drive Thousand Oaks CA United States of America 91320-1799
- IPO Date
- Jun 17, 1983
- CIK
- 0000318154
- Website
- amgen.com
- Similar Companies
- Business
- Amgen Inc. discovers, develops, manufactures and delivers innovative human therapeutics worldwide, focusing on biotechnology to treat serious illnesses in oncology, inflammation, cardiovascular disease, bone health, nephrology, neuroscience and rare diseases. Headquartered in Thousand Oaks, California, the company was founded in 1980 as Applied Molecular Genetics and pioneered the biotechnology industry with recombinant DNA technology. Amgen operates globally with manufacturing facilities in the United States, Ireland, Puerto Rico, Singapore, the Netherlands and other locations, serving patients through wholesalers and healthcare providers. The company's principal products include Prolia and Xgeva (denosumab) for osteoporosis and bone diseases; Enbrel (etanercept) for autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis and plaque psoriasis; Repatha (evolocumab) for hyperlipidemia; Otezla (apremilast) for psoriasis and psoriatic arthritis; Tepezza (teprotumumab) for Graves' ophthalmopathy; Evenity (romosozumab) for osteoporosis; Kyprolis (carfilzomib) for multiple myeloma; Nplate (romiplostim) for thrombocytopenia; Aranesp (darbepoetin alfa) for anemia; Neulasta (pegfilgrastim) and Neupogen (filgrastim) for neutropenia; Epogen (epoetin alfa) for anemia; Aimovig (erenumab) for migraine; Blincyto (blinatumomab) for acute lymphoblastic leukemia; Lumakras (sotorasib) for KRAS G12C-mutated non-small cell lung cancer; Tezspire (tezepelumab) for severe asthma; Vectibix (panitumumab) for colorectal cancer; Parsabiv (etelcalcetide) for secondary hyperparathyroidism; biosimilars such as Amjevita (adalimumab), Mvasi (bevacizumab), Kanjinti (trastuzumab), Riabni (rituximab) and Avsola (infliximab); and rare disease therapies including Krystexxa (pegloticase), Uplizna (inebilizumab) and Tavneos (avacopan). Amgen maintains a robust pipeline with 17 Phase III programs, including MariTide (maridebart cafraglutide), an investigational once-monthly anti-obesity therapy; Imdelltra (tarlatamab), a bispecific T-cell engager for extensive-stage small cell lung cancer; and advancements in oncology, cardiovascular and rare disease areas. Recent developments include major manufacturing expansions with a $650 million investment at its Juncos, Puerto Rico facility announced in September 2025 to enhance biologics production and create nearly 750 jobs; a $900 million expansion at its New Albany, Ohio biomanufacturing plant in April 2025; a $600 million Center for Science and Innovation at its Thousand Oaks headquarters broken ground in October 2025; and a $1 billion project at its Holly Springs, North Carolina site. In August 2025, Royalty Pharma acquired a royalty interest in Amgen's Imdelltra from BeOne Medicines for $885 million upfront. The company strengthened its portfolio through acquisitions including Horizon Therapeutics for $27.8 billion in 2023 adding Tepezza, Krystexxa and Uplizna; ChemoCentryx for $3.7 billion in 2022 adding Tavneos; and others such as Otezla from Celgene in 2019. Amgen continues collaborations like those with Kyowa Kirin, AstraZeneca and Generate Biomedicines, while advancing AI partnerships with Amazon Web Services for drug discovery announced in 2023.
Company News
Amgen Highlights 26% Growth Drivers, IMDELLTRA Momentum and MariTide Potential
Amgen Drops 10% on a Trial It Didn't Even Run
Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Are Medical Stocks Lagging Amgen (AMGN) This Year?
Amgen (AMGN) Dips More Than Broader Market: What You Should Know
Amgen Inc. (AMGN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study
Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
Here Are Thursday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Amgen, AngloGold Ashanti, Caterpillar, Chewy, Meta Platforms, Novartis, NVIDIA, SK hynix, and More
Amgen: Buy The Novartis-Driven Selloff (Rating Upgrade)
AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
Invesco Pharmaceuticals vs iShares Healthcare: Which Healthcare ETF Brings Better Profits
Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%
Disappointing Clinical Trial Results Are Dragging Novartis, Amgen and the Dow Lower Tuesday
Tuesday's First Moves: BE Joining SPX, AMGN & NVS Fall, PANW Downgrade
Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus
IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Amgen, Baidu, Best Buy, Circle Internet, Corning, Intel, Lockheed Martin SpaceX, TeraWulf and More
Intel, Amgen, Novartis, Bloom Energy, and More Stocks That Explain Today's Market